CD22 and acute lymphoblastic leukemia: We postulated that residual wildtype CD22 with undeleted exon 12 could compensate for the missing inhibitory function of the truncated CD22 molecules and thereby mitigate the net effect of the CD22ΔE12 splicing defect on B-ALL cells [12,13].